Egger, Matthias http://orcid.org/0000-0002-7795-4406
Salmanton-García, Jon http://orcid.org/0000-0002-6766-8297
Barac, Aleksandra http://orcid.org/0000-0002-0132-2277
Gangneux, Jean-Pierre http://orcid.org/0000-0002-4974-5607
Guegan, Hélène
Arsic-Arsenijevic, Valentina http://orcid.org/0000-0001-8132-3300
Matos, Tadeja http://orcid.org/0000-0002-5696-1412
Tomazin, Rok
Klimko, Nikolai http://orcid.org/0000-0001-6095-7531
Bassetti, Matteo http://orcid.org/0000-0002-0145-9740
Hammarström, Helena http://orcid.org/0000-0002-5859-1056
Meijer, Eelco F. J. http://orcid.org/0000-0002-0226-024X
Meis, Jacques F. http://orcid.org/0000-0003-3253-6080
Prattes, Juergen http://orcid.org/0000-0001-5751-9311
Krause, Robert http://orcid.org/0000-0001-6656-3648
Resat Sipahi, Oguz http://orcid.org/0000-0002-1243-2746
Scharmann, Ulrike http://orcid.org/0000-0001-7689-7799
White, P. Lewis http://orcid.org/0000-0003-3056-4205
Desoubeaux, Guillaume http://orcid.org/0000-0001-7945-9890
García-Rodríguez, Julio http://orcid.org/0000-0002-3771-8740
Garcia-Vidal, Carolina http://orcid.org/0000-0002-8915-0683
Martín-Pérez, Sonia http://orcid.org/0000-0001-5809-7165
Ruiz, Maite
Tumbarello, Mario
Talento, Alida Fe http://orcid.org/0000-0003-1271-2550
Rogers, Benedict http://orcid.org/0000-0002-7041-6744
Lagrou, Katrien http://orcid.org/0000-0001-8668-1350
van Praet, Jens http://orcid.org/0000-0002-7125-7001
Arikan-Akdagli, Sevtap http://orcid.org/0000-0001-9807-6764
Arendrup, Maiken C. http://orcid.org/0000-0002-4747-0144
Koehler, Philipp http://orcid.org/0000-0002-7386-7495
Cornely, Oliver A. http://orcid.org/0000-0001-9599-3137
Hoenigl, Martin http://orcid.org/0000-0002-1653-2824
Alastruey-Izquierdo, Ana
de Jonge, Nick Alexander
Bicanic, Tihana
Blennow, Ola
Denis, Blandine
Khanna, Nina
Lass-Flörl, Cornelia
Logan, Clare
Loughlin, Laura
Özenci, Volkan
Zdenek, Zdenek
Rahimli, Laman
Rautemaa-Richardson, Riina
Steinmann, Joerg
Stoma, Igor
Trauth, Janina
Danion, François
Buil, Jochem B.
Dávila-Valls, Julio
van Wijngaerden, Eric
,
Funding for this research was provided by:
Medical University of Graz
Article History
Received: 3 June 2023
Accepted: 11 July 2023
First Online: 11 August 2023
Declarations
:
: MH reports grants and research funding from Astellas, Gilead, MSD, Pfizer, Euroimmun, F2G, Pulmocide, IMMY, Mundipharma and Scynexis. JSG has received lecture honoraria from Gilead and Pfizer, outside of the submitted work. JPG has received lecture honoraria from Gilead, MundiPharma and Pfizer, outside of the submitted work. TB reports receipt of speaker fees, advisory Board fees and research fellowship funding from Gilead sciences, research grants from Pfizer and MSD and advisory Board fees from Mundipharma. SAA reports research grant from Cidara, lecture honoraria from Gilead, and travel grant from Astellas. AA-I has received honoraria for educational talks of behalf of Gilead and Pfizer, outside of the submitted work. NK was a speaker for Astellas, Gilead Sciences, Merck/MSD, and Pfizer and an adviser for Gilead Sciences, Merck/MSD, and Pfizer, all outside the submitted work. KL received consultancy fees from MRM Health, MSD and Gilead, speaker fees from FUJIFILM WAKO, Pfizer and Gilead and a service fee from Thermo fisher Scientific and TECOmedical NKh is a member of the Gilead, Merck Sharp & Dohme AG (MSD) and Pfizer advisory boards for invasive fungal infections, chair of the DSMB of Pulmocide, and reports grants from The Swiss National Science Foundation (grant number 32003B_204944 and the National Centre of Competence in Research AntiResist Grant 51NF40_180541), outside the submitted work. MB reports research grants and/or personal fees for advisor/consultant and/or speaker/chairman from Bayer, BioMérieux, Cidara, Cipla, Gilead, Menarini, MSD, Pfizer, and Shionogi. MA had research grants from Pfizer, honoraria from Pfizer, Gilead and, Sanofi for contributing educational activities which were paid to the university funds; none related with the submitted work. BD reports receipt of speaker fees, advisory Board fees from Gilead sciences, advisory Board fees from Pfizer, outside the submitted work. FD declares personal fees from Gilead, Pfizer, outside the submitted work. GD has received lecture honoraria from Gilead and Pfizer, outside of the submitted work. He was also invited to symposia and congresses by the two aforementioned companies. LD reports lecture honoraria from Pfizer, MSD and Teva, outside the submitted work Outside the submitted work, DRG reports investigator-initiated grants from Pfizer, Shionogi, and Gilead Italia and speaker fees and/or advisory board fees from Pfizer and Tillotts Pharma. FD declares personal fees from Gilead and Pfizer, outside the submitted work.AG reports COI with the following companies: JANNSEN, VIIV, MSD, BMS, ABBVIE, GILEAD, NOVARTIS, PFIZER, ASTELLAS, ASTRAZENECA, ANGELINI CGV reports Grant support from Gilead and MSA, and personal fees from Gilead Science, MSD, Novartis, Pfizer, Janssen, Lilly. FL reports receipt of speaker fees from Gilead, Pfizer and F2G and advisory board fees from F2G MM has received speaker fees from Janssen, Gilead, Mundipharma, MSD and Pfizer ORS has received speaker's honorarium from Astellas, Pfizer and Kocak Farma. ER reports grants to his institutions from Astellas, MSD, Scynexis, Shionogi, GSK, Pfizer, Gilead and Allergan. He has served as consultant to Amplyx, Astellas, Gilead, MSD, Pfizer, Scynexis, GSK and Shionogi. JP has received research funding from MSD and Pfizer and lecture honoraria from Gilead Sciences, Pfizer, Associates of Cape Cod and Swedish Orphan Biovitrium GmbH, outside of the submitted work. JS has received lecture honoraria from Gilead and Pfizer, outside of the submitted work BW reports personal fees from MSD, Pfizer, Gilead, Shionogi, Euroimmun, Immy, CapeCod and grants to her institution from Pfizer, Shionogi and AMT has received lecture honoraria from Gilead MCA has, over the past 5 years, received research grants/contract work (paid to the SSI) from Amplyx, Basilea, Cidara, F2G, Gilead, and Scynexis, and speaker honoraria (personal fee) from Astellas, Chiesi, Gilead, MSD, SEGES and F2G. She is the current chairman of the EUCAST-AFST PK reports grants or contracts from German Federal Ministry of Research and Education (BMBF) B-FAST (Bundesweites Forschungsnetz Angewandte Surveillance und Testung) and NAPKON (Nationales Pandemie Kohorten Netz, German National Pandemic Cohort Network) of the Network University Medicine (NUM) and the State of North Rhine-Westphalia; Consulting fees Ambu GmbH, Gilead Sciences, Mundipharma Resarch Limited, Noxxon N.V. and Pfizer Pharma; Honoraria for lectures from Akademie für Infektionsmedizin e.V., Ambu GmbH, Astellas Pharma, BioRad Laboratories Inc., Datamed GmbH, European Confederation of Medical Mycology, Gilead Sciences, GPR Academy Ruesselsheim, HELIOS Kliniken GmbH, Lahn-Dill-Kliniken GmbH, medupdate GmbH, MedMedia GmbH, MSD Sharp & Dohme GmbH, Pfizer Pharma GmbH, Scilink Comunicación Científica SC, streamedup! GmbH and University Hospital and LMU Munich; Participation on an Advisory Board from Ambu GmbH, Gilead Sciences, Mundipharma Resarch Limited and Pfizer Pharma; A pending patent currently reviewed at the German Patent and Trade Mark Office (DE 10 2021 113 007.7); Other non-financial interests from Elsevier, Wiley and Taylor & Francis online outside the submitted work. OAC reports grants and personal fees from Actelion, personal fees from Allecra Therapeutics, personal fees from Al-Jazeera Pharmaceuticals, grants and personal fees from Amplyx, grants and personal fees from Astellas, grants and personal fees from Basilea, personal fees from Biosys, grants and personal fees from Cidara, grants and personal fees from DaVolterra, personal fees from Entasis, grants and personal fees from F2G, grants and personal fees from Gilead, personal fees from Grupo Biotoscana, personal fees from IQVIA, grants from Janssen, personal fees from Matinas, grants from Medicines Company, grants and personal fees from MedPace, grants from Melinta Therapeutics, personal fees from Menarini, grants and personal fees from Merck/MSD, personal fees from Mylan, personal fees from Nabriva, personal fees from Noxxon, personal fees from Octapharma, personal fees from Paratek, grants and personal fees from Pfizer, personal fees from PSI, personal fees from Roche Diagnostics, grants and personal fees from Scynexis, personal fees from Shionogi, grants from DFG, German Research Foundation, grants from German Federal Ministry of Research and Education, grants from Immunic, personal fees from Biocon, personal fees from CoRe Consulting, personal fees from Molecular Partners, from MSG-ERC, from Seres, other from Wiley (Blackwell), outside the submitted work. AFT has received speaker honoraria from Pfizer Ireland and Gilead Sciences and research grants from Gilead Sciences outside the submitted work. PLW: Performed diagnostic evaluations and received meeting sponsorship from Associates of Cape Cod, Bruker, Dynamiker, IMMY and Launch Diagnostics; Speaker’s fees, expert advice fees and meeting sponsorship from Gilead; and speaker and expert advice fees from Pfizer and expert advice fees from F2G and Mundipharma. RK received research grants from Merck and Pfizer and speaker honoraria from Pfizer, Gilead, Astellas, Basilea, Merck, Angelini and Shionogi HH has received speaker honoraria from Gilead Sciences, Sanofi and Novartis as well as honorarium for antifungal workshops through Daman P/S, all outside the submitted work All other authors declare no conflict of interest for this study.